$6.07
42.15%
Nasdaq, Apr 21, 08:50 pm CET
ISIN
US92829J1043
Symbol
DWTX
Sector
Industry

Virios Therapeutics Inc Stock price

$4.27
-1.82 29.89% 1M
+0.26 6.48% 6M
+1.78 71.49% YTD
-7.00 62.12% 1Y
-98.85 95.86% 3Y
-245.73 98.29% 5Y
-245.73 98.29% 10Y
Nasdaq, Closing price Thu, Apr 17 2025
+0.54 14.48%
ISIN
US92829J1043
Symbol
DWTX
Sector
Industry

Key metrics

Market capitalization $8.16m
Enterprise Value $83.30m
P/E (TTM) P/E ratio negative
EV/FCF (TTM) EV/FCF negative
P/B ratio (TTM) P/B ratio negative
Revenue (TTM) Revenue $0.00
EBIT (operating result TTM) EBIT $-12.23m
Free Cash Flow (TTM) Free Cash Flow $-8.79m
Cash position $14.85m
EPS (TTM) EPS $-11.17
P/E forward negative
Short interest 6.78%
Show more

Is Virios Therapeutics Inc a Top Scorer Stock based on the Dividend, High-Growth-Investing or Leverman Strategy?

As a Free StocksGuide user, you can view scores for all 6,780 stocks worldwide.

Virios Therapeutics Inc Stock Analysis

Unlock Scores for Free

Analyst Opinions

1 Analyst has issued a forecast Virios Therapeutics Inc:

1x Buy
100%

Analyst Opinions

1 Analyst has issued a forecast Virios Therapeutics Inc:

Buy
100%

Financial data from Virios Therapeutics Inc

Income Statement P&L | Balance Sheet | Cash Flow


Quarter TTM Annually
Dec '24
+/-
%
- -
-
100%
- Direct Costs 0.01 0.01
-
-
-0.01 -0.01
-
-
- Selling and Administrative Expenses 8.67 8.67
133% 133%
-
- Research and Development Expense 3.53 3.53
104% 104%
-
-12 -12
124% 124%
-
- Depreciation and Amortization 0.01 0.01
-
-
EBIT (Operating Income) EBIT -12 -12
124% 124%
-
Net Profit -12 -12
133% 133%
-

In millions USD.

Don't miss a Thing! We will send you all news about Virios Therapeutics Inc directly to your mailbox free of charge.

If you wish, we will send you an e-mail every morning with news on stocks of your portfolios.

Virios Therapeutics Inc Stock News

Neutral
GlobeNewsWire
10 days ago
ATLANTA, April 11, 2025 (GLOBE NEWSWIRE) -- Dogwood Therapeutics, Inc. (Nasdaq: DWTX) (the “Company”), a development-stage biopharmaceutical company focused on developing new medicines to treat pain and fatigue-related disorders, today announced that it has received written confirmation from Nasdaq that it has regained compliance with Nasdaq Listing Rule 5550(b)(1), which requires minimum stock...
Neutral
GlobeNewsWire
18 days ago
ATLANTA, April 03, 2025 (GLOBE NEWSWIRE) -- Dogwood Therapeutics, Inc. (Nasdaq: DWTX) (the “Company”), a development-stage biopharmaceutical company focused on developing new medicines to treat pain and fatigue-related disorders today announced it believes it has regained compliance with the minimum stockholders' equity requirement as set forth in Nasdaq Listing Rule 5550(b)(1). DWTX Chairman a...
Neutral
GlobeNewsWire
21 days ago
-Dogwood Therapeutics, Inc. commenced dosing of patients in the Halneuron® Chemotherapy Induced Neuropathic Pain (“CINP”) Phase 2b Trial -
More Virios Therapeutics Inc News

Company Profile

Virios Therapeutics, Inc. is a clinical-stage biopharmaceutical company, which engages in the development and commercialization of antiviral therapies to treat diseases associated with a viral triggered abnormal immune response including fibromyalgia. It offers IMC-1 a novel, proprietary, fixed dose combination of famciclovir and celecoxib. The company was founded by William L. Pridgen on February 28, 2012 and is headquartered in Alpharetta, GA.

Head office United States
CEO Gregory Duncan
Employees 12
Founded 2012
Website www.dwtx.com

Register for Free

StocksGuide is the ultimate tool for easily finding, analyzing and tracking stocks. Learn from successful investors and make informed investment decisions. We empower you to become a confident, independent investor.

The Apple stock at a glance with charts, current key metrics, news and stock analyses.
The Best Dividend Stocks in the Dividend Top Scorer list.
Stock Analyses of the Best Stocks Worldwide.
Start building wealth today